Changes in Insulin Requirements From the Onset of Continuous Subcutaneous Insulin Infusion (CSII) Until Optimization of Glycemic Control

Eitemau Tebyg

• Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
  gan: Li, Feng-fei, et al.
  Cyhoeddwyd: (2018)
• Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy.
  gan: Lawson, P M, et al.
  Cyhoeddwyd: (1982)
• A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
  gan: King, Allen B., et al.
  Cyhoeddwyd: (2016)
• Carbohydrate-to-Insulin Ratio in a Mediterranean Population of Type 1 Diabetic Patients on Continuous Subcutaneous Insulin Infusion Therapy
  gan: Alcántara-Aragón, Valeria, et al.
  Cyhoeddwyd: (2014)
• Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
  gan: Lyu, Fu-ping, et al.
  Cyhoeddwyd: (2020)